Sfoglia per RIVISTA
HAEMATOLOGICA
Collezione AOU San Luigi di Orbassano

  

Items : 41

Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study. in Haematologica / Haematologica. 2024 Aug 15. doi: 10.3324/haematol.2024.285638.

2024
AOU Novara
AOU Città della Salute di Torino
AOU San Luigi di Orbassano
AO Ordine Mauriziano

Candoni A; Foa R; Ferrara F; Pizzolo G; Bassan R; Starza ID; Fanin R; Luppi M; Marsili G; Vignetti M; Piciocchi A; Mancini V; De Bellis E; Trastulli F; Ciccone M; De Gobbi M; Cignetti A; Mazzone C; Aprile L; Mauro E; Fanin M; Chiusolo P; Minetto P; Defina M; Delia M; Pasciolla C; Grimaldi F; Cambo B; Santoro L; et alii...

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry. in Haematologica / Haematologica. 2024 Aug 1;109(8):2693-2700. doi: 10.3324/haematol.2023.284678.

2024
AOU Alessandria
AOU San Luigi di Orbassano

Pagano L; Study Group E; Garcia-Vidal C; Cornely OA; Hersby DS; Rahimli L; Grafe S; Colak GM; Limongelli A; Bavastro M; Prin R; Wolf D; Ammatuna E; Arellano E; Nordlander A; Cabirta A; Cordoba R; Tragiannidis A; Rodrigues RN; Garcia-Bordallo D; Mitrovic M; Lievin R; Hanakova M; Ra?il Z; Vehreschild M; Garcia-Sanz R; Varricchio G; Cvetanoski M; Emarah Z; et alii...

Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from three decades of follow-up in a high-income setting. in Haematologica / Haematologica. 2023 Apr 1;108(4):1158-1162. doi: 10.3324/haematol.2022.280815.

2023
ASL Torino 4
AOU San Luigi di Orbassano

Piga A; Maggio A; Cappellini MD; Mazzi F; Spadola V; Graziadei G; Quota A; Rigano P; Longo F; Gianesin B; Piel FB; Pinto VM; De Franceschi L; Forni GL;

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. in Haematologica / Haematologica. 2022 Oct 1;107(10):2356-2364. doi: 10.3324/haematol.2021.280175.

2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Baccarani M; Cavo M; Saglio G; Pane F; Foà R; Simula MP; Albano F; Soverini S; Porretto F; Sorà F; Cavazzini F; Trabacchi E; Cedrone M; Bocchia M; Tiribelli M; Martino B; Rege-Cambrin G; Salvucci M; Stagno F; D'Adda M; Intermesoli T; Levato L; Breccia M; Castagnetti F; Gugliotta G; Rosti G;

Tricuspid-valve regurgitant jet velocity as a risk factor for death in ?-thalassemia. in Haematologica / Haematologica. 2022 Jul 1;107(7):1714-1718. doi: 10.3324/haematol.2021.280389.

2022
ASL Torino 4
AOU San Luigi di Orbassano

Cappellini MD; Piga A; Perrotta S; Tartaglione I; Gianesin B; Ameri P; Merella P; Miceli R; Casale M; Longo F; Pasanisi A; Casu G; Origa R; Barella S; Giuditta M; Graziadei G; Pinto VM; Musallam KM; Derchi G; Forni GL;

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. in Haematologica / Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

2019
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria

Tarella C; Ladetto M; Corradini P; Passera R; Gianni AM; Rambaldi A; Billio A; Gueli A; Mantoan B; Angrilli F; Perrone T; Semenzato G; Lanza F; Parvis G; Dondi A; Narni F; Zallio F; Zoli V; Devizzi L; Tucci A; Rota-Scalabrini D; Di Raimondo F; Stelitano C; Ciceri F; Rossini F; Castellino C; Gini G; Liberati AM; Musso M; et alii...

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. in Haematologica / Haematologica. 2017 Sep;102(9):1530-1536. doi: 10.3324/haematol.2017.169532. Epub 2017 Jun 1.

2017
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Gugliotta G; Castagnetti F; Breccia M; Albano F; Iurlo A; Intermesoli T; Abruzzese E; Levato L; D'Adda M; Pregno P; Cavazzini F; Stagno F; Martino B; La Barba G; Sorà F; Tiribelli M; Bigazzi C; Binotto G; Bonifacio M; Caracciolo C; Soverini S; Foà R; Cavo M; Martinelli G; Pane F; Saglio G; Baccarani M; Rosti G;

Pleural effusion in dasatinib-treated CML patients: Incidence and management in a real-life Italian multicenter series in Haematologica

2017
AOU San Luigi di Orbassano

Iurlo A; Galimberti S; Abruzzese E; Annunziata M; Bonifacio M; Latagliata R; Pregno P; Ferrero D; Sorà F; Orlandi E; Fava C; Cattaneo D; Bucelli C; Binotto G; Pioltelli ML; Tiribelli M; Gozzini A; Gugliotta G; Castagnetti F; Stagno F; Rege-Cambrin G; Martino B; Luciano L; Consonni D; Breccia M; Sica S; Bocchia M; Rosti G; Specchia G; et alii...

Tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia: A retrospective analysis of 208 Italian patients in Haematologica

2017
AOU San Luigi di Orbassano

Fava C; Rege-Cambrin G; Dogliotti I; Berchialla P; Cerrano M; Rosti G; Castagnetti F; Gugliotta G; Martino B; Gambacorti-Passerini C; Abruzzese E; Orlandi E; Chiara E; Pregno P; Gozzini A; Avanzini P; Bergamaschi M; Crugnola M; Bocchia M; Galimberti S; Rapezzi D; Iurlo A; Cattaneo D; Latagliata R; Breccia M; Cedrone M; Santoro M; Annunziata M; Levato L; et alii...

Rate and reasons of 5-azacytidine discontinuation and subsequent therapeutic options in 418 MDS patients from the Italian MDS registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM) in Haematologica

2017
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Clavio M; Gioia D; Ceccarelli M; Monagheddu C; Balleari E; Miglino M; Di Tucci AA; Allione B; Poloni A; Finelli C; Aguzzi C; Selleri C; Danise P; Cilloni D; Gaidano V; Cavaliere M; Calzamiglia T; Freilone R; Cametti G; Conconi AR; Mezzabotta M; Goretti R; Musto P; Gaidano G; Pane F; Angelucci E; Levis A; Santini V;

The automated molecular technique “ultra” allows a sensitive and accurate BCR-ABL1 quantification in patients affected by chronic myeloid leukemia in Haematologica

2017
AOU San Luigi di Orbassano

Guerrini F; Izzo B; Gottardi E; Bochicchio MT; Morganti R; Grassi S; Barate C; Erricchiello S; Pedri R; Metelli MR; Lorenzatti R; Di Vita A; Domenichini C; Saglio G; Pane F; Petrini M; Martinelli G; Galimberti S;

Long-term follow-up in very elderly patients with chronic myeloid leukemia treated with imatinib frontline in Haematologica

2017
AOU San Luigi di Orbassano

Crugnola M; Latagliata R; Breccia M; Ferrero D; Trawinska MM; Castagnetti F; Annunziata M; Stagno F; Tiribelli M; Binotto G; Fava C; Cris E; Mansueto G; Gozzini A; Falzetti F; Montefusco E; Iurlo A; Russo S; Cedrone M; Russo Rossi A; Gugliotta G; Pregno P; Isidori A; Mauro E; Atelda R; Giglio G; Celesti F; Sor F; Storti S; et alii...

Rate and causes of 5-azacytidine discontinuation and subsequent therapeutic options in 418 MDS patients from the Italian MDS registry of fondazione Italiana sindromi mielodisplastiche (FISM) in Haematologica

2017
ASL Biella
ASL Torino 5
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Mezzabotta M; Conconi AR; Cametti G; Freilone R; Calzamiglia T; Cavaliere M; Gaidano V; Cilloni D; Danise P; Selleri C; Aguzzi C; Finelli C; Poloni A; Allione B; Di Tucci AA; Miglino M; Balleari E; Monagheddu C; Ceccarelli M; Gioia D; Clavio M; Santini V; Gaidano G; Pane F; Angelucci E; Levis A; Goretti R; Musto P;

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. in Haematologica / Haematologica. 2016 Oct;101(10):1200-1207. doi: 10.3324/haematol.2016.144949. Epub 2016 Jul 28.

2016
AOU San Luigi di Orbassano

Castagnetti F; Breccia M; Gugliotta G; Martino B; D'Adda M; Stagno F; Carella AM; Avanzini P; Tiribelli M; Trabacchi E; Visani G; Gobbi M; Salvucci M; Levato L; Binotto G; Capalbo SF; Bochicchio MT; Soverini S; Cavo M; Martinelli G; Alimena G; Pane F; Saglio G; Rosti G; Baccarani M;

Chronic myeloid leukemia with extreme thrombocytocis at the diagnosis: A new subset in Haematologica

2016
AOU San Luigi di Orbassano

Sorà F; Alessandra I; Latagliata R; Castagnetti F; Fava C; Annunziata M; Gozzini A; Montefusco E; Avanzini P; Pregno P; Cerrano M; Celesti F; Galimberti S; Bocchia M; Breccia M; Cattaneo D; Rosti G; Sica S;

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. in Haematologica / Haematologica. 2015 Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. Epub 2015 Jun 25.

2015
AOU San Luigi di Orbassano

Gugliotta G; Castagnetti F; Breccia M; Levato L; D'Adda M; Stagno F; Tiribelli M; Salvucci M; Fava C; Martino B; Cedrone M; Bocchia M; Trabacchi E; Cavazzini F; Usala E; Russo Rossi A; Bochicchio MT; Soverini S; Alimena G; Cavo M; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G;

Comparison of droplet digital PCR and standard PCR in chronic myeloid leukemia patients in MR4 in Haematologica

2015
AOU San Luigi di Orbassano

Fava C; Gottardi E; Berchialla P; Rege-Cambrin G; Varotto M; Daraio F; Crasto F; Lorenzatti R; Volpengo A; Fantino C; Dani N; Barberio D; Dogliotti I; Saglio G;

Long-term outcome of alternating nilotinib 400 mg twice daily and imatinib 400 mg once daily as first-line treatment of chronic myeloid leukemia: A phase 2 study of the gimema cml working party in Haematologica

2015
AOU San Luigi di Orbassano

Gugliotta G; Castagnetti F; Breccia M; Gozzini A; Stagno F; Rege-Cambrin G; Carella AM; Luciano L; Specchia G; Abruzzese E; Martino B; Usala E; Rossi G; Bocchia M; Cavazzini F; Tiribelli M; Venturi C; Soverini S; Alimena G; Cavo M; Pane F; Martinelli G; Saglio G; Rosti G; Baccarani M;

BCR-ABL inactivates cytosolic pten through casein kinase II mediated tail phosphorylation in Haematologica

2014
AOU San Luigi di Orbassano

Morotti A; Panuzzo C; Crivellaro S; Carrà G; Guerrasio A; Pandolfi PP; Saglio G;

Cytogenetic response, molecular response and outcome of elderly PH+ CML patients with stable complete cytogenetic response after 4-years of intermittent treatment with imatinib (interim) in Haematologica

2013
AOU San Luigi di Orbassano

Russo D; Malagola M; Martinelli G; Skert C; Soverini S; Iacobucci I; De Vivo A; Testoni N; Castagnetti F; Gugliotta G; Turri D; Bergamaschi M; Pregno P; Pungolino E; Stagno F; Breccia M; Martino B; Intermesoli T; Fava C; Abruzzese E; Tiribelli M; Bigazzi C; Cesana BM; Rosti G; Baccarani M;

Low doses of dasatinib are safe and effective in elderly patients with chronic myeloid leukemia resistant/intolerant to imatinib in Haematologica

2013
AOU San Luigi di Orbassano

Porrini R; Latagliata R; Breccia M; Stagno F; Luciano L; Gozzini A; Gugliotta G; Fava C; Cavazzini F; Annunziata M; Sica S; Russo Rossi A; Pregno P; Abruzzese E; Crisà E; Mansueto G; Tiribelli M; Binotto G; Occhini U; Feo C; Iurlo A; Capodanno I; Crugnola M; Isidori A; Calistri E; Cedrone M; Martino B; Cavalli L; Castagnetti F; et alii...

High eutos score is predictive for adverse outcome in early chronic phase CML patients treated with nilotinib-based regimens in Haematologica

2012
AOU San Luigi di Orbassano

Castagnetti F; Gugliotta G; Palandri F; Breccia M; Levato L; Stagno F; Rege Cambrin G; Luciano L; Specchia G; Abruzzese E; Gozzini A; Martino B; Capucci A; Intermesoli T; Tiribelli M; Cedrone M; Cavazzini F; Soverini S; Testoni N; Saglio G; Martinelli G; Pane F; Alimena G; Rosti G; Baccarani M;

Frontline nilotinib 400 mg bid in early chronic phase chronic myeloid leukemia: Stable results beyond 4 years-the gimema CML WP trial CML0307 in Haematologica

2012
AOU San Luigi di Orbassano

Gugliotta G; Castagnetti F; Breccia M; Levato L; Capucci A; Tiribelli M; Zaccaria A; Bocchia M; Cuneo A; Stagno F; Specchia G; Musso M; Martino B; Cedrone M; Intermesoli T; Palandri F; Soverini S; Baldazzi C; Durante S; Testoni N; Alimena G; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G;

A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: Three centres experience in Haematologica

2012
AOU San Luigi di Orbassano

Ferrero D; Crisà E; Rege-Cambrin G; Fava C; Cerrano M; Pirillo F; Nicolosi M; Boccadoro M; Saglio G; Vitolo U; Pregno P;

Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) vs bortezomib, melphalan, prednisone (VMP) alone as first line tratment of multiple myeloma: Updated follow-up and impact of prognostic factors in Haematologica

2011
AOU San Luigi di Orbassano

Bringhen S; Magarotto V; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Callea V; Pescosta N; Di Renzo N; Giuliani N; Capparella V; Aschero S; Petrucci MT; Musto P; Di Raimondo F; Gaidano G; Boccadoro M; Palumbo A;

VMPT (bortezomib, melphalan, prednisone and thalidomide) followed by maintenance with bortezomib-thalidomide (VT) is active and well tolerated in newly diagnosed patients with multiple myeloma (MM) with moderate renal impairment (RI) ineligible for autologous stem cell transplantation: Results from a cohort analysis of a phase III randomized controlled trial in Haematologica

2011
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Morabito F; Gentile M; Mazzone C; Rossi D; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci M; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Musto P; Liberati A; Cascavilla N; Cangialosi C; Majolino I; Musolino C; Zambello R; Di Raimondo F; Cavo M; Boccadoro M; Palumbo A;

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. in Haematologica / Haematologica. 2010 Aug;95(8):1308-16. doi: 10.3324/haematol.2009.016824. Epub 2010 Jun 9.

2010
AOU San Luigi di Orbassano

Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D;

Charlson comorbidities index (CCI) may predict compliance and development of pleural effusions in elderly chronic myeloid leukemia (CML) resistant/intolerant patients treated with dasatinib in Haematologica

2010
AOU San Luigi di Orbassano

Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Ulisciani S; Cavazzini F; Annunziata M; Sorà F; Russo Rossi A; Pregno P; Porrini R; Abruzzese E; Giai V; Musto P; Tiribelli M; Binotto G; Occhini U; Vallone R; Martino B; Capodanno I; Spina F; Pane F; Santini V; Rosti G; Fava C; Alimena G;

Factors influencing the occurrence of secondary myelodysplastic syndrome/acute leukemia following high-dose therapy and autograft: A GITIL (Gruppo Italiano Terapie innovative nei linfomi) survey in 1,347 lymphoma patients in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Passera R; Magni M; Rossi A; Gueli A; Benedetti F; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Corradini P; Zoli V; Leone M; Bosa M; Barbui A; Di Nicola M; Boccadoro M; Sorio M; Gianni AM; Rambaldi A;

Studies on c-KIT protein expression and c-KIT gene mutation in multiple myeloma in Haematologica

2009
AOU San Luigi di Orbassano

Merlini R; Serra A; Giugliano E; Pautasso M; Cappia S; Capotti M; Guglielmelli T; Saglio G;

Limited stage low-grade lymphoma patients receiving Rituximab combined with localized radiotherapy: The long-term follow-up shows prolonged survival with low incidence of disease recurrence in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Caracciolo D; Ruella M; Bazzan M; Parvis G; Ladetto M; Boccadoro M; Mistretta A; Patti C; Todisco L; Franco P; Ricardi U; Filippi AR;

Histology and rituximab addition are the main factors influencing the long-term outcome in high-risk lymphoma following high-dose therapy and autograft: A 20-yr. Follow-up in 1,347 patients by gitil (gruppo italiano terapie innovative NEI Linfomi) in Haematologica

2009
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tarella C; Di Nicola M; Rossi A; Caracciolo D; Passera R; Benedetti F; Patti C; Parvis G; Ciceri F; Castellino C; Cortelazzo S; Corradini P; Majolino I; Mule' A; Bosa M; Barbui A; Magni M; Boccadoro M; Sorio M; Rambaldi A; Gianni AM;

The long-term durability of molecular responses in patients with FIP1L1-PDGFRA chronic heosinophilic leukemia treated with imatinib: The italian hes0203 experience after a 4-year follow-up in Haematologica

2009
AOU San Luigi di Orbassano

Rondoni M; Cilloni D; Paolini S; Ottaviani E; Messa F; Piccaluga PP; Merante S; Buccisano F; Titibelli M; Vigna E; Spadea A; Messa E; Pane F; Saglio G; Lauria F; Baccarani M; Martinelli G;

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. in Haematologica / Haematologica. 2008 Jun;93(6):921-4. doi: 10.3324/haematol.12165. Epub 2008 Apr 28.

2008
AOU San Luigi di Orbassano

Cilloni D; Messa F; Arruga F; Defilippi I; Gottardi E; Fava M; Carturan S; Catalano R; Bracco E; Messa E; Nicoli P; Diverio D; Sanz MA; Martinelli G; Lo-Coco F; Saglio G;

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR?- positive hypereosinophilic syndrome. Results of a multicenter prospective study in Haematologica

2007
AOU San Luigi di Orbassano

Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; De Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G;

Hepatic expression of hemochromatosis genes in two mouse strains after phlebotomy and iron overload. in Haematologica / Haematologica. 2005 Sep;90(9):1161-7.

2005
AOU San Luigi di Orbassano

Bondi A; Valentino P; Daraio F; Porporato P; Gramaglia E; Carturan S; Gottardi E; Camaschella C; Roetto A;

Two new translocations involving the 11q23 region map outside the MLL locus in myeloid leukemias. in Haematologica / Haematologica. 2002 Oct;87(10):1014-20.

2002
AOU San Luigi di Orbassano

Giugliano E; Rege-Cambrin G; Scaravaglio P; Wlodarska I; Emanuel B; Stul M; Serra A; Tonso A; Pini M; Saglio G; Hagemeijer A;

Recurrent mutations in the iron regulatory element of L-ferritin in hereditary hyperferritinemia-cataract syndrome. in Haematologica / Haematologica. 1999 Jun;84(6):489-92.

1999
AOU San Luigi di Orbassano

Cicilano M; Zecchina G; Roetto A; Bosio S; Infelise V; Stefani S; Mazza U; Camaschella C;

Feasibility of molecular diagnosis of alpha-thalassemia in the evaluation of microcytosis. in Haematologica / Haematologica. 1997 Sep-Oct;82(5):592-3.

1997
AOU San Luigi di Orbassano

Sivera P; Roetto A; Mazza U; Camaschella C;

Hereditary hemochromatosis: recent advances in molecular genetics and clinical management. in Haematologica / Haematologica. 1997 Jan-Feb;82(1):77-84.

1997
AOU San Luigi di Orbassano

Camaschella C; Piperno A;

Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective. in Haematologica / Haematologica. 1995 Sep-Oct;80(5):454-72.

1995
AOU San Luigi di Orbassano

Gaidano G; Pastore C; Volpe G;